| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.12. | BillionToOne, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.12. | BillionToOne stock rating reiterated at Overweight by Piper Sandler | 2 | Investing.com | ||
| 10.12. | BillionToOne Q3 2025 presentation slides: Revenue soars 117% as profitability achieved | 1 | Investing.com | ||
| 09.12. | BillionToOne appoints Genmab CFO Anthony Pagano to board | 13 | Investing.com | ||
| 09.12. | BillionToOne, Inc. GAAP EPS of $0.10 misses by $0.22, revenue of $83.5M beats by $0.6M | 1 | Seeking Alpha | ||
| 09.12. | BillionToOne, Inc.: BillionToOne Reports Third Quarter 2025 Results | 54 | GlobeNewswire (Europe) | MENLO PARK, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen | |
| 09.12. | BillionToOne, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.12. | BillionToOne, Inc.: BillionToOne to Report Third Quarter 2025 Financial Results on December 9, 2025 | 2 | GlobeNewswire (USA) | ||
| BILLIONTOONE Aktie jetzt für 0€ handeln | |||||
| 01.12. | Analysts See Big Upside For Newly Listed Molecular Diagnostic Firm BillionToOne After Standout IPO Rally | 3 | Benzinga.com | ||
| 01.12. | BTIG initiates BillionToOne stock with Buy rating on prenatal testing growth | 1 | Investing.com | ||
| 01.12. | BillionToOne stock initiated at Equal Weight by Wells Fargo with $110 target | 4 | Investing.com | ||
| 01.12. | BillionToOne: Wells Fargo startet Coverage mit "Equal Weight" und Kursziel 110 US-Dollar | 4 | Investing.com Deutsch | ||
| 01.12. | JPMorgan startet Coverage für BillionToOne mit "Overweight" | 1 | Investing.com Deutsch | ||
| 01.12. | Jefferies startet Coverage für BillionToOne mit "Halten"-Rating und Kursziel von 117 $ | 4 | Investing.com Deutsch | ||
| 01.12. | Piper Sandler initiates BillionToOne stock coverage with Overweight rating | 1 | Investing.com | ||
| 01.12. | BillionToOne stock initiated at Overweight by JPMorgan on diagnostic tech | 2 | Investing.com | ||
| 01.12. | Jefferies initiates BillionToOne stock with Hold rating, $117 price target | 2 | Investing.com | ||
| 01.12. | Stifel startet Coverage für BillionToOne mit Kaufempfehlung wegen NIPT-Marktanteilsgewinnen | 2 | Investing.com Deutsch | ||
| 01.12. | BillionToOne stock initiated with Buy rating at Stifel on NIPT market share gains | 3 | Investing.com | ||
| 10.11. | BillionToOne, Inc. - 8-K, Current Report | - | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 44,640 | +0,97 % | Moody's vergibt Investmentgrade-Rating "A3" an Siemens Healthineers | DJ Moody's vergibt Investmentgrade-Rating "A3" an Siemens Healthineers
DOW JONES--Moody's hat Siemens Healthineers die Bonitätsbewertung A3 gegeben, was als sichere Anlage gilt. Der Ausblick ist... ► Artikel lesen | |
| FRESENIUS | 47,780 | +0,74 % | JPMORGAN stuft Fresenius SE auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Fresenius mit einem Kursziel von 53,60 Euro auf "Overweight" belassen. Die Veranstaltung mit dem Biopharma-Management der Bad... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,300 | +0,30 % | Fresenius Medical Care ernennt neuen Chief Medical Officer | DJ Fresenius Medical Care ernennt neuen Chief Medical Officer
DOW JONES--Fresenius Medical Care bekommt einen neuen Chief Medical Officer. Wie der Dialysespezialist mitteilte, hat er Charles Hugh-Jones... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 40,000 | +0,15 % | UBS stuft CARL ZEISS MEDITEC AG auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Carl Zeiss Meditec mit einem Kursziel von 53 Euro auf "Neutral" belassen. Die Suche nach einem neuen Chef laufe, aber werde... ► Artikel lesen | |
| HEARTBEAM | 3,100 | -10,14 % | Heartbeam stock is a buy, this analyst says | ||
| GERRESHEIMER | 26,880 | -0,67 % | UBS stuft GERRESHEIMER AG auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Gerresheimer nach einem "Report" eines Leerverkäufers mit einem Kursziel von 29 Euro auf "Neutral" belassen. Er habe bereits... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 35,810 | -1,74 % | BrightSpring upgraded at KeyBanc on specialty pharmacy and EBITDA prospects | ||
| PROGYNY | 25,970 | -0,23 % | Progyny, Inc. - 8-K, Current Report | ||
| ALIGNMENT HEALTHCARE | 20,470 | +2,20 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 34,810 | -2,36 % | UBS stuft Procept BioRobotics mit "Buy" ein - Wachstum bei Systemauslastung als Treiber | ||
| ECKERT & ZIEGLER | 14,650 | -1,08 % | EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Eckert & Ziegler SE
Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective... ► Artikel lesen | |
| CLEARPOINT NEURO | 14,640 | +5,78 % | ClearPoint Neuro, Inc.: ClearPoint Neuro Completes Acquisition of IRRAS | Acquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation SOLANA BEACH, CALIFORNIA / ACCESS Newswire... ► Artikel lesen | |
| CASTLE BIOSCIENCES | 39,910 | +2,18 % | Castle Biosciences, Inc.: Systematic Review and Meta-Analysis Confirms TissueCypher Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer | FRIENDSWOOD, Texas, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication... ► Artikel lesen | |
| NUTEX HEALTH | 165,02 | -3,86 % | Nutex Health, Inc.: Nutex Health Responds To Short Seller Report | HOUSTON, Nov. 26, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), is aware of a short seller report issued on November... ► Artikel lesen | |
| BETA BIONICS | 29,760 | +0,44 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen |